Has anyone else considered the fact that companies like Pfizer and Sanofi are buying out small biotechs? Is it any coincidence that Dr. Urbanski (Pfizer) and Dr. Clarence-Smith (Sanofi) are now working with GTBP? Would it make sense for them to tap their previous industry colleagues at these companies and show them the opportunity and potential of GTBP for a possible strategic investment?
Considering the company will begin stage 2 of clinical trials on its motion sickness treatment soon, it is easy to imagine the stock being north of $2 within the next few months.